Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Kopran Ltd (KOPRAN)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524280 NSE: KOPRAN Pharmaceuticals & Drugs | Small Cap | Kopran Share Price
₹190.15 9.05 (5.00%)
As on 14-Aug'26 16:59
Kopran Ltd (KOPRAN)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524280 NSE: KOPRAN Pharmaceuticals & Drugs | Small Cap | Kopran Share Price
₹190.15 9.05 (5.00%)
As on 14-Aug'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹918 Cr.
Current Price
₹190.2
52-Week Low / High
₹107 / 219
TTM EPS
₹7
TTM Sales
₹317 Cr.
Book Value per Share
₹93.9
P/E Ratio
27.32
Lower than its 5-year historical median
Industry PE
53.5
Price to Book (P/B)
2.03
Lower than its 5-year historical median
Price to Sales (P/S)
2.90
Lower than its 5-year historical median
EV/EBITDA
17.80
Lower than its 5-year historical median
Dividend Yield
1.58%
Profitability Efficiency
Return on Equity (ROE)
6.94%
Underperforms industry median
Return on Capital Employed (ROCE)
9.19%
Underperforms industry median
Return on Assets (ROA)
5.28%
Operating Profit Margin
16.7%
Net Profit Margin
9.95%
Gross Profit Margin
14.9%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
12.78%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
23.1%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
13.18%
Asset Quality
Promoter Holding
44.42%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹405 Cr.
Equity
₹48.3 Cr.
Face Value
₹10
All Time Low / High
₹6.40 / 558.84
Check Before You Invest
Quality
Locked
Login to view analysis.
Valuation
Locked
Login to view analysis.
Price Trend
Locked
Login to view analysis.
Is Kopran Ltd a good quality company?
Kopran Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Kopran Ltd performance compare with that of its Peers?
Revenue growth of Kopran Ltd vs industry peers?
Kopran Ltd revenue CAGR is 6.52%, compared to the industry median CAGR of 5.75%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Kopran Ltd?
Promoters hold 44.42% of the Kopran Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Kopran Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 15.7% based on the current price.
10 Year X-Ray : Login to view analysis.
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Kopran Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 9.5% | 5.3% | 8.7% | 8% | 13.6% | 5.6% | 9.4% | 11.4% | 8.6% | 9.2% | - |
| Value Creation Index ⓘ | -0.3 | -0.6 | -0.4 | -0.4 | 0.0 | -0.6 | -0.3 | -0.2 | -0.4 | -0.3 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 182 | 154 | 197 | 179 | 223 | 205 | 273 | 337 | 271 | 306 | 317 |
| Sales YoY Gr. | - | -15.3% | 27.9% | -8.8% | 24.3% | -8.2% | 33.5% | 23.6% | -19.7% | 12.8% | - |
| Adj EPS ⓘ | 0.6 | 0 | 3.1 | 2.6 | 4.1 | 1.8 | 6.4 | 6.6 | 5.2 | 6.8 | 7 |
| YoY Gr. | - | -96.8% | 15250% | -14% | 54.2% | -54.8% | 249.5% | 1.9% | -21.2% | 32% | - |
| BVPS (₹) ⓘ | 46.5 | 47.6 | 50.5 | 53.1 | 57.1 | 78.6 | 82.1 | 86.3 | 89 | 92.5 | 93.9 |
| Adj Net Profit ⓘ | 2.7 | 0.1 | 13.3 | 11.4 | 17.6 | 8.9 | 31 | 31.6 | 24.9 | 32.9 | 34 |
| Cash Flow from Ops. ⓘ | 4.2 | 12.5 | 11.8 | 10 | 48.8 | -37.8 | 16.9 | 35 | 23.3 | 29.7 | - |
| Debt/CF from Ops. ⓘ | 13.4 | 4.2 | 4.2 | 4.6 | 0.3 | -1 | 1.7 | 0.7 | 1.9 | 1.6 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 6% | 6.5% | 3.8% | 12.8% | ||||
| Adj EPS ⓘ | 30.5% | 10.8% | 1.9% | 32% | ||||
| BVPSⓘ | 8% | 10.1% | 4.1% | 3.9% | ||||
| Share Price | 15.7% | -1.9% | 4.4% | 20.9% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 1.4 | 0 | 6.3 | 5.1 | 7.4 | 2.8 | 8 | 7.8 | 5.9 | 7.5 | 7.5 |
| Op. Profit Mgn % ⓘ | 9.6 | 4.7 | 11.8 | 13.1 | 13.5 | 7.5 | 10.4 | 10.9 | 14.3 | 16.7 | 17.2 |
| Net Profit Mgn % ⓘ | 1.5 | 0.1 | 6.8 | 6.4 | 7.9 | 4.3 | 11.4 | 9.4 | 9.2 | 10.8 | 10.6 |
| Debt to Equity ⓘ | 0.3 | 0.3 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | - |
| Working Cap Days ⓘ | 188 | 233 | 186 | 229 | 187 | 236 | 231 | 204 | 255 | 265 | 140 |
| Cash Conv. Cycle ⓘ | 25 | 48 | 42 | 84 | 55 | 87 | 83 | 73 | 110 | 111 | 60 |
Valuation of Kopran - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 182 | 154 | 197 | 179 | 223 | 205 | 273 | 337 | 271 | 306 |
| Operating Expenses ⓘ + | 164 | 146 | 174 | 156 | 193 | 189 | 245 | 301 | 232 | 258 |
| Operating Profit ⓘ | 17 | 7 | 23 | 23 | 30 | 15 | 28 | 37 | 39 | 48 |
| Operating Profit Margin (%) | 9.6% | 4.7% | 11.5% | 12.9% | 13.5% | 7.5% | 10.2% | 10.9% | 14.3% | 15.6% |
| Other Income ⓘ + | 9 | 10 | 3 | 2 | 10 | 8 | 16 | 17 | 6 | 2 |
| Interest ⓘ | 10 | 7 | 5 | 6 | 4 | 3 | 3 | 5 | 4 | 4 |
| Depreciation ⓘ | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 5 | 5 | 5 |
| Profit Before Tax ⓘ | 13 | 7 | 17 | 16 | 33 | 16 | 37 | 45 | 36 | 40 |
| Tax ⓘ | 5 | 2 | 4 | 5 | 9 | 4 | 6 | 10 | 9 | 10 |
| Profit After Tax | 9 | 5 | 13 | 11 | 23 | 12 | 31 | 35 | 27 | 30 |
| PAT Margin (%) | 4.7% | 3.1% | 6.6% | 6.3% | 10.5% | 5.7% | 11.4% | 10.3% | 9.9% | 10.0% |
| Adjusted EPS (₹) | 2.0 | 1.1 | 3.0 | 2.6 | 5.4 | 2.4 | 6.5 | 7.2 | 5.6 | 6.3 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 27.60% | 123.20% | 46.30% | 41.80% | 53.90% | 47.70% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 201 | 206 | 218 | 230 | 247 | 379 | 396 | 416 | 430 | 446 | |
| Debt + | 50 | 45 | 41 | 36 | 16 | 37 | 28 | 23 | 45 | 46 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 36 | 29 | 32 | 32 | 40 | 30 | 62 | 52 | 46 | 76 | |
| Others Liabilities ⓘ | 19 | 17 | 24 | 28 | 22 | 19 | 20 | 21 | 25 | 38 | |
| Total Liabilities ⓘ | 306 | 297 | 316 | 326 | 324 | 464 | 506 | 511 | 546 | 606 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 39 | 38 | 42 | 43 | 47 | 46 | 47 | 52 | 61 | 82 | |
| CWIP ⓘ | 4 | 8 | 7 | 7 | 3 | 3 | 4 | 5 | 7 | 8 | |
| Investments ⓘ | 157 | 157 | 158 | 158 | 159 | 259 | 260 | 261 | 263 | 265 | |
| Inventories | 25 | 30 | 25 | 41 | 28 | 42 | 48 | 49 | 56 | 66 | |
| Trade Receivables | 38 | 20 | 45 | 42 | 49 | 59 | 84 | 88 | 92 | 133 | |
| Cash Equivalents | 2 | 2 | 1 | 1 | 3 | 3 | 3 | 7 | 21 | 2 | |
| Others Assets ⓘ | 40 | 42 | 39 | 33 | 35 | 52 | 61 | 48 | 46 | 51 | |
| Total Assets ⓘ | 306 | 297 | 316 | 326 | 324 | 464 | 506 | 511 | 546 | 606 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 4 | 12 | 12 | 10 | 49 | -38 | 17 | 35 | 23 | 30 |
| Cash Flow From Investing Activity ⓘ + | -9 | -2 | -4 | 1 | -9 | -100 | 10 | -6 | -15 | -30 |
| Cash Flow From Financing Activity ⓘ + | 5 | -11 | -7 | -11 | -40 | 138 | -26 | -24 | 6 | -19 |
| Net Cash Flow ⓘ | -0 | -0 | -0 | 0 | 0 | -0 | 1 | 5 | 14 | -19 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 4.37 | 2.31 | 6.12 | 5.01 | 9.85 | 3.75 | 8.07 | 8.54 | 6.35 | 6.94 |
| ROCE (%) | 9.5 | 5.28 | 8.67 | 7.98 | 13.57 | 5.64 | 9.44 | 11.36 | 8.63 | 9.19 |
| Asset Turnover Ratio | 0.62 | 0.51 | 0.64 | 0.56 | 0.69 | 0.52 | 0.56 | 0.66 | 0.51 | 0.53 |
| PAT to CFO Conversion(x) | 0.44 | 2.4 | 0.92 | 0.91 | 2.13 | -3.17 | 0.55 | 1 | 0.85 | 1 |
| Working Capital Days | ||||||||||
| Receivable Days | 58.20 | 69.40 | 60 | 88.60 | 75.30 | 96.90 | 95.50 | 92.80 | 121 | 134.10 |
| Inventory Days | 53.50 | 65.10 | 50.90 | 67.50 | 56.20 | 61.60 | 59.50 | 52.50 | 70.80 | 72.60 |
| Payable Days | 136.80 | 153.70 | 109.20 | 133.70 | 105.90 | 119 | 107.50 | 101.50 | 136.40 | 154.10 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Kopran Ltd FAQs
The current trading price of Kopran on 14-Aug-2026 16:59 is ₹190.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 13-Aug-2026 the market cap of Kopran stood at ₹918.1 Cr
The latest P/E ratio of Kopran as of 13-Aug-2026 is 27.32.
The latest P/B ratio of Kopran as of 13-Aug-2026 is 2.03.
The 52-week high of Kopran is ₹218.9 and the 52-week low is ₹107.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kopran is ₹317 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Kopran Ltd is a average quality company.
The key valuation ratios of Kopran Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Kopran Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Kopran Ltd
The company was incorporated on April 26, 1958 as a private limited company under the name Kopran Chemical Company Pvt. Ltd. by Ramanlal V Shah Sevantilal, A Shah , Chimanlal G Sheth and Jivanalal M Shah. In 1972, the company’s management was acquired by Chemo Pharma Laboratories Ltd and the Company’s products were marketed by them.
Promoted by the Parijat Enterprises, Kopran is currently an integrated health care company. Kopran has used research-based technology to contribute towards total health-care. The company started modestly as a Semi Synthetic Penicillin (SSP) player and expanded to becomes the largest SSP Player in India with an annual SSP facility of over 1200 tones per annum.Subsequently the SSP business was hived off into a separate Company in a joint venture with Synpac Pharmaceuticals Ltd, UK.Kopran Laboratories Ltd. markets and supports high-tech life-saving medical equipments and diagnostics reagents since 1988.
Kopran Research Laboratories Ltd. (KRLL) is an emerging research organisation with particular interests in the areas of drug discovery, polymer technology and synthesis of new molecules.
Kopran is working towards creating and maintaining a global presence.Presence in Africa through Kampala Pharmaceutical Industries (KPI),a pharmaceutical company engaged in the manufacture and marketing of finished dosage forms in Uganda.
The company is having presence in the Middle East Market through a joint venture with Dubai Investment Corporation a leading investment company in Dubai for the manufacture and marketing of finished dosage forms in Dubai.
KRLL is a 100% subsidiary of Kopran Ltd. KRLL is recognised by the Department of Science and Industrial Research (DSIR), Government of India. The company is staffed with competent and dedicated team of scientists.
Product range of the company includes:
Finished Dosage Forms
- Antibiotics/antibacterials
- Anti-malarial
- Cadiovasculars
- Pain management
- Anthelminthics
- Antiprotozoals
- Antidiabetics
- Gastrointestinals
- Drug for erectile dysfuntion
- Antiallergics
- Respiratory/anti-asthmatics
- Metered dose inhalers
- Dry powder inhalers
- Antiviral
Active Pharmaceutical Ingredients
- Anti-hypertensives
- Macrolides
- Taste Masked
- Cephalosporins
- Under Development
- Others
Achievements/ recognition:
- Kopran has a state of art manufacturing plants (Penicillin & General) approved by: -MCC (South Africa) -TGA, Australia and FDA, USA are in the pipeline
Future plans:
- Brand Equity Development
- Research for New Chemical Entities
- Globalise its operations thus making Kopran a truly International Pharmaceutical Company.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
